-
What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.
Access to HealthcareClinical ResearchEthical BusinessMedicine Safety -
Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.
Access to HealthcareClinical ResearchDrug DevelopmentInfectious DiseasesTropical Diseases -
Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.
CancerClinical ResearchInnovationOncologyScientific Research -
Basel, Switzerland, December 16, 2019 – Novartis today announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily, DP2 receptor antagonist fevipiprant (QAW039). The pooled analyses of the LUSTER trials did not meet3 the clinically relevant…RespiratoryClinical ResearchAd Hoc
-
Basel, April 22, 2020 — Data from the Phase III REACH2 study published today in The New England Journal of Medicine show Jakavi® (ruxolitinib) improves outcomes across a range of efficacy measures in patients with steroid-refractory acute graft-versus-host disease (GvHD) compared to best available therapy (BAT). The results of REACH2, the first…Reimagine MedicineInnovationClinical Research
-
Novartis researchers are working to extend the life of organ transplants
InnovationMedical InnovationsNovartis Institutes for BioMedical ResearchClinical ResearchClinical Trials -
Novartis investigators find genetic explanations for why some young patients relapse.
CancerCell and Gene TherapyNovartis Institutes for BioMedical ResearchClinical ResearchClinical Trials -
A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.
COVID-19DigitalClinical ResearchClinical TrialsClinical ScienceDrug Development -
Chinweike Ukomadu thinks that notions about clinicians turning their backs on patients when transitioning to industry are outdated.
Novartis Institutes for BioMedical ResearchClinical ResearchCareersClinical TrialsClinical Science -
Myriam Mendila describes how Novartis continued supporting cancer patients and healthcare professionals during the pandemic.
Access to HealthcareCancerCOVID-19OncologyWorking at NovartisClinical Research -
Read how nature's medicine chest empowers our drug discovery chemists to advance biomedical research
Drug DiscoveryGene SequencingNovartis Institutes for BioMedical ResearchClinical ResearchBiomedical JobsDrug Design -
Novartis taps MOOC technology to share chemistry education with the world
Drug DiscoveryNovartis Institutes for BioMedical ResearchTropical DiseasesClinical ResearchBiomedical JobsEye Disorders
Pagination
- 1
- 2
- › Next page